These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1125 related articles for article (PubMed ID: 34299137)

  • 21. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
    Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
    Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS.
    Ishida T; Ishii Y; Tsuruta M; Okabayashi K; Akimoto S; Koishikawa K; Hasegawa H; Kitagawa Y
    Oncol Rep; 2017 Aug; 38(2):926-932. PubMed ID: 28656305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer.
    Yang J; Mo J; Dai J; Ye C; Cen W; Zheng X; Jiang L; Ye L
    Cell Death Dis; 2021 Nov; 12(11):1079. PubMed ID: 34775496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
    Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
    Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
    E J; Xing J; Gong H; He J; Zhang W
    Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
    Jing C; Wang T; Ma R; Cao H; Wang Z; Liu S; Chen D; Zhang J; Wu Y; Zhang Y; Wu J; Feng J
    Mol Carcinog; 2020 May; 59(5):478-491. PubMed ID: 32141150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab.
    Bellier J; Nokin MJ; Caprasse M; Tiamiou A; Blomme A; Scheijen JL; Koopmansch B; MacKay GM; Chiavarina B; Costanza B; Rademaker G; Durieux F; Agirman F; Maloujahmoum N; Cusumano PG; Lovinfosse P; Leung HY; Lambert F; Bours V; Schalkwijk CG; Hustinx R; Peulen O; Castronovo V; Bellahcène A
    Cell Rep; 2020 Feb; 30(5):1400-1416.e6. PubMed ID: 32023458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer.
    Ohnami S; Maruyama K; Chen K; Takahashi Y; Hatakeyama K; Ohshima K; Shimoda Y; Sakai A; Kamada F; Nakatani S; Naruoka A; Ohnami S; Kusuhara M; Akiyama Y; Kagawa H; Shiomi A; Nagashima T; Urakami K; Yamaguchi K
    Mol Cell Biochem; 2021 Sep; 476(9):3469-3482. PubMed ID: 33982211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
    Kochi M; Hinoi T; Niitsu H; Miguchi M; Saito Y; Sada H; Sentani K; Sakamoto N; Oue N; Tashiro H; Sotomaru Y; Yasui W; Ohdan H
    Cancer Sci; 2020 Oct; 111(10):3540-3549. PubMed ID: 32629543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
    Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
    Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-5p/PIK3R3/AKT axis.
    Xu H; Liu Y; Cheng P; Wang C; Liu Y; Zhou W; Xu Y; Ji G
    J Exp Clin Cancer Res; 2020 Dec; 39(1):283. PubMed ID: 33317596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
    Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
    J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.
    Guinney J; Ferté C; Dry J; McEwen R; Manceau G; Kao KJ; Chang KM; Bendtsen C; Hudson K; Huang E; Dougherty B; Ducreux M; Soria JC; Friend S; Derry J; Laurent-Puig P
    Clin Cancer Res; 2014 Jan; 20(1):265-272. PubMed ID: 24170544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
    Tian S; Simon I; Moreno V; Roepman P; Tabernero J; Snel M; van't Veer L; Salazar R; Bernards R; Capella G
    Gut; 2013 Apr; 62(4):540-9. PubMed ID: 22798500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-141-3p affected proliferation, chemosensitivity, migration and invasion of colorectal cancer cells by targeting EGFR.
    Xing Y; Jing H; Zhang Y; Suo J; Qian M
    Int J Biochem Cell Biol; 2020 Jan; 118():105643. PubMed ID: 31704502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.